Adagio Medical Holdings, Inc ADGM

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
21/100
Weak

Ranked against 159 peers in Medical Devices

About Adagio Medical Holdings, Inc

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial … Full ADGM analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.93). Improving FCF margin signals compounding operational leverage.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.01). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.23). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
2
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where ADGM ranks in Medical Devices

Adagio Medical Holdings, Inc ranks #140 of 160 scored companies in Medical Devices by moat score — the top 88%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
136 Bluejay Diagnostics, Inc. BJDX 23/100 Weak
137 COCHW COCHW 22/100 Weak
138 Envoy Medical, Inc. COCH 22/100 Weak
139 Autonomix Medical, Inc. AMIX 21/100 Weak
140 Adagio Medical Holdings, Inc ADGM 21/100 Weak
141 Tivic Health Systems, Inc. TIVC 20/100 Weak
142 HeartSciences Inc. HSCS 18/100 Weak
143 Heart Test Laboratories, Inc. W HSCSW 18/100 Weak
144 Sera Prognostics, Inc. SERA 18/100 Weak

See every Medical Devices & Diagnostics company ranked by moat score →

How ADGM scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 2 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 26 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 44 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 5 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 31 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 22 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding ADGM's moat

What is Adagio Medical Holdings, Inc's moat score?

Adagio Medical Holdings, Inc (ADGM) scores 21 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #140 of 160 scored companies in Medical Devices, the top 88%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is FCF Quality & Cash Conversion (44/100) and its weakest is Pricing Power & Consumable Moat (2/100).

How does Adagio Medical Holdings, Inc compare with other Medical Devices companies?

Adagio Medical Holdings, Inc ranks #140 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Autonomix Medical, Inc. (AMIX) at 21 just above it and Tivic Health Systems, Inc. (TIVC) at 20 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Adagio Medical Holdings, Inc scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Adagio Medical Holdings, Inc?

The Medical Devices & Diagnostics template measures 6 defenses, and ADGM scores: Pricing Power & Consumable Moat (2), R&D Pipeline & Capital Returns (26), FCF Quality & Cash Conversion (44), Commercial Execution (5), Capital Structure & Resilience (31), Growth Durability (22). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000